Fig. 1: Prior treatment, clinical genomics, and response to camonsertib.
From: Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma
A Treatment history from diagnosis through TRESR trial. B TVR counts derived from Telomere Hunter analysis of WGS data in the tumor compared to blood normal sample collected from this patient. C A representative confocal microscopy image of the ssTeloC foci (green) detected in the retroperitoneal metastatic biopsy (scale bar = 20 µm). The pie chart shows the proportion of cells with various numbers of the foci from the total number of cells analyzed (N = 44,616). Scans of the peritoneal mass at (D) baseline (3.3 cm × 3.2 cm), and 11 months on treatment (0.0 cm × 0.0 cm). E RECIST v1.1 measurements at baseline and on-treatment. Green box indicates −30% change from baseline. F Longitudinal ctDNA monitoring was performed using tumor uninformed variant-based approach using Tempus xF and methylation-based circulating tumor fraction estimation using Guardant Infinity™, and a tumor-informed dPCR based approach from Tracer Biotechnologies. Approximate LOQs for each assay type are marked in the dotted lines.
